Dronedarone for atrial fibrillation therapy

References

• Go AS, Hylek EM, Philips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA285, 2370–2375 (2001).
   PubMed Web of Science ®Google Scholar
• Tsang TS, Gersh BJ. Atrial fibrillation: an old disease, a new epidemic. Am. J. Med.113, 432–435 (2002).
   PubMed Web of Science ®Google Scholar
• Bialy D, Lehmann MH, Schumacher DN et al. Hospitalization for arrhythmia in the United States: importance of atrial fibrillation (Abstract). J. Am. Coll. Cardiol.19, 41A (1992).
   Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. Arch. Intern. Med.147, 1561–1564 (1987).
   PubMed Web of Science ®Google Scholar
• Wolf PA, Dawber TR, Thomas HE et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology28, 973–977 (1978).
   PubMed Web of Science ®Google Scholar
• Pedersen OD, Abildstrom SZ, Ottesen MM et al. Increased risk of sudden and non-sudden cardiovascular death in patients with atrial fibrillation/flutter following acute myocardial infarction. Eur. Heart J.27, 290–295 (2006).
   PubMed Web of Science ®Google Scholar
• Tsang TS, Miyasaka Y, Barnes ME, Gersh BJ. Epidemiological profile of atrial fibrillation: a contemporary perspective. Prog. Cardiovasc. Dis.48, 1–8 (2005).
   PubMed Web of Science ®Google Scholar
• Miyasaka Y, Barnes ME, Gersh BJ et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation114, 119–125 (2006).
   PubMed Web of Science ®Google Scholar
• Lundstrom T, Ryden L. Chronic atrial fibrillation. Long term results of direct current cardioversion. Acta Med. Scand.223, 53–59 (1988).
   PubMedGoogle Scholar
• Coplen SE, Antman E, Berlin JA et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized controlled trials. Circulation83, 1106–1116 (1990).
   Google Scholar
• The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Guidelines for the management of atrial fibrillation. Eur. Heart J.31(19), 2369–2429 (2010).
   PubMed Web of Science ®Google Scholar
• Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med.347, 1825–1834 (2002).
   PubMed Web of Science ®Google Scholar
• Sherman DG, Kim SG, Boop BS et al. for the National Heart, Lung, and Blood Institute AFFIRM Investigators. Occurrence and characteristics of stroke events in the atrial fibrillation follow-up investigation of sinus rhythm management (AFFIRM) study. Arch. Intern. Med.165, 1185–1191 (2005).
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in AF (PIAF): a randomized trial. Lancet365, 1789–1794 (2000).
   Google Scholar
• Saxonhouse SJ, Curtis AB. Risks and benefits of rate control versus maintenance of sinus rhythm. Am. J. Cardiol.91, 27–32 (2003).
   PubMed Web of Science ®Google Scholar
• Nattel S, Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Am. J. Cardiol.5, 1034–1049 (2006).
   Google Scholar
• Nattel S, Opie LH. Controversies in atrial fibrillation. Lancet367, 262–272 (2006).
   PubMed Web of Science ®Google Scholar
• Riley MJ, Marrouche NF. Ablation of atrial fibrillation. Curr. Probl. Cardiol.31, 361–390 (2006).
   PubMed Web of Science ®Google Scholar
• Oral H, Morady F. How to select patients for atrial fibrillation ablation. Heart Rhythm5, 615–618 (2006).
   Google Scholar
• Chun SH, Sager PT, Stevenson WG et al. Chronic atrial fibrillation. Long term results of direct current cardioversion. Acta Med. Scand.223, 53–59 (1988).
   PubMedGoogle Scholar
• Roy D, Talajic M, Dorian P et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N. Engl. J. Med.342, 913–920 (2000).
   PubMed Web of Science ®Google Scholar
• Vorperian VR, Havighurst TC, Miller S et al. Adverse effects of low dose amiodarone: a meta-analysis. J. Am. Coll. Cardiol.30, 791–798 (1997).
   PubMed Web of Science ®Google Scholar
• Zareba KM. Dronedarone: a new antiarrhythmic agent. Drugs Today (Barc.)42, 75–86 (2006).
   PubMed Web of Science ®Google Scholar
• Wegener FT, Ehrlich JR, Hohnloser SH. Dronedarone: an emerging agent with rhythm- and rate-controlling effects. J. Cardiovasc. Electrophysiol.17(Suppl. 2), S17–S20 (2006).
   PubMed Web of Science ®Google Scholar
• Gautier P, Marion A, Bertrand JP, Tourneur Y, Nisato D. Electrophysiological characteristics of dronedarone (SR33589), a new amiodarone-like agent, in cardiac ventricular myocytes. Eur. Heart J.18(Suppl.), 269 (1997).
   Google Scholar
• Sun W, Sarma JS, Singh BN. Electrophysiological effects of dronedarone (SR33589), a non-iodinated benzofuran derivative in the rabbit heart: comparison with amiodarone. Circulation100, 2276–2281 (1999).
   PubMed Web of Science ®Google Scholar
• Sun W, Sarma JS, Singh BN. Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone. J. Cardiovasc. Pharmacol.39, 677–684 (2002).
   PubMed Web of Science ®Google Scholar
• Varro A, Biliczki P, Iost N et al. Theoretical possibilities for the development of novel antiarrhythmic drugs. Curr. Med. Chem.11, 1–11 (2004).
   PubMed Web of Science ®Google Scholar
• Doggrell SA, Hancox JC. Dronedarone: an amiodarone analogue. Expert Opin. Investig. Drugs13, 415–426 (2004).
   PubMed Web of Science ®Google Scholar
• Varro A, Takacs J, Nemeth M et al. Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: Comparison with amiodarone. Br. J. Pharmacol.133, 625–634 (2001).
   PubMed Web of Science ®Google Scholar
• Gautier P, Guillemare E, Marion A et al. Electrophysiologic characterization of dronedarone in guinea pig ventricular cells. J. Cardiovasc. Pharmacol.41, 191–202 (2003).
   PubMed Web of Science ®Google Scholar
• Lalevee N, Nargeot J, Barrere-Lemaire S, Gautier P, Richard S. Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes. J. Cardiovasc. Electrophysiol.14, 885–890 (2003).
   PubMed Web of Science ®Google Scholar
• Chatelain P, Meysmans L, Matteazzi JR, Beaufort P, Clinet M. Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the β2-adrenoceptor and adenylate cyclase in the rat heart. Br. J. Pharmacol.116, 1949–1956 (1995).
   PubMed Web of Science ®Google Scholar
• Hodeige D, Heyndrickx JP, Chatelain P, Manning A. SR 33589, a new amiodarone-like antiarrhythmic agent: anti-adrenoceptor activity in anaesthetized and conscious dogs. Eur. J. Pharmacol.279, 25–32 (1995).
   PubMed Web of Science ®Google Scholar
• Dale KM, White CM. Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann. Pharmacother.41, 599–605 (2007).
   PubMed Web of Science ®Google Scholar
• Multaq ® (dronedarone), product information. © sanofi-aventis, Ambares, France.
   Google Scholar
• Dobrev D, Nattel S. New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet375, 1212–1223 (2010).
   PubMed Web of Science ®Google Scholar
• Tschuppert Y, Buclin T, Rothuizen LE et al. Effect of dronedarone on renal function in healthy subjects. Br. J. Clin. Pharmacol.64, 785–791 (2007).
   PubMed Web of Science ®Google Scholar
• Tuboul P, Brugada J, Capucci A et al. Dronedarone for prevention of atrial fibrillation: A dose-ranging study. Eur. Heart J.24, 1481–1487 (2003).
   PubMed Web of Science ®Google Scholar
• Singh BN, Connolly SJ, Crijns HJ et al.; for the EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N. Engl. J. Med.357, 987–999 (2007).
   PubMed Web of Science ®Google Scholar
• Davy JM, Herold M, Hoglund C et al.; for the ERATO Study Investigators. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and Safety of Dronedarone for the Control of Ventricular Rate During Atrial Fibrillation (ERATO) study. Am. Heart J.156(3), 527.e1–9 (2008).
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Crijns HJ, van Eickels M et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N. Engl. J. Med.360, 668–678 (2009).
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Crijns HJ, Torp-Pedersen C et al. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation120, 1174–1180 (2009).
   PubMed Web of Science ®Google Scholar
• de Denus S, Sanoski CA, Carlsson J, Opolski G, Spinler SA. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis. Arch. Intern. Med.165, 258–262 (2005).
   PubMed Web of Science ®Google Scholar
• Kober L, Torp-Pedersen C, McMurray JJ et al.; for the Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N. Engl. J. Med.358, 2678–2687 (2008).
   PubMed Web of Science ®Google Scholar
• Le Heuzey JY, de Ferrari GM, Radzik D et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J. Cardiovasc. Electrophysiol.21, 597–605 (2010).
   PubMed Web of Science ®Google Scholar
• Piccini JP, Hasselblad V, Peterson ED et al. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J. Am. Coll. Card.54, 1089–1095 (2009).
   PubMed Web of Science ®Google Scholar
• Wann LS, Curtis AB, January CT et al.; for the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline). Heart Rhythm8, 157–176 (2011).
   PubMed Web of Science ®Google Scholar